BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis
Europe - FRA:BSX - US1011371077 - Common Stock
86.2 EUR
-0.2 (-0.23%)
Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 60 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of BSX get a neutral evaluation. Nothing too spectacular is happening here. BSX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
BSX had positive earnings in the past year.
BSX had a positive operating cash flow in the past year.
BSX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years BSX had a positive operating cash flow.
1.2 Ratios
BSX has a Return On Assets of 6.03%. This is in the better half of the industry: BSX outperforms 70.00% of its industry peers.
BSX's Return On Equity of 11.17% is fine compared to the rest of the industry. BSX outperforms 70.00% of its industry peers.
BSX has a Return On Invested Capital of 7.66%. This is in the better half of the industry: BSX outperforms 65.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 9.00%.
The last Return On Invested Capital (7.66%) for BSX is above the 3 year average (6.54%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
BSX has a Profit Margin of 13.54%. This is in the better half of the industry: BSX outperforms 80.00% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
The Operating Margin of BSX (18.69%) is better than 83.33% of its industry peers.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
With a decent Gross Margin value of 68.30%, BSX is doing good in the industry, outperforming 78.33% of the companies in the same industry.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BSX is destroying value.
BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
BSX has a worse debt/assets ratio than last year.
2.2 Solvency
BSX has an Altman-Z score of 5.52. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
BSX's Altman-Z score of 5.52 is amongst the best of the industry. BSX outperforms 86.67% of its industry peers.
BSX has a debt to FCF ratio of 3.33. This is a good value and a sign of high solvency as BSX would need 3.33 years to pay back of all of its debts.
BSX's Debt to FCF ratio of 3.33 is fine compared to the rest of the industry. BSX outperforms 73.33% of its industry peers.
BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BSX (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.52 |
ROIC/WACC0.93
WACC8.27%
2.3 Liquidity
BSX has a Current Ratio of 1.37. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, BSX perfoms like the industry average, outperforming 45.00% of the companies in the same industry.
A Quick Ratio of 0.82 indicates that BSX may have some problems paying its short term obligations.
BSX has a Quick ratio of 0.82. This is in the lower half of the industry: BSX underperforms 61.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
The Earnings Per Share has been growing by 9.56% on average over the past years. This is quite good.
The Revenue has grown by 21.62% in the past year. This is a very strong growth!
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.40% on average per year.
The Revenue is expected to grow by 12.12% on average over the next years. This is quite good.
EPS Next Y20.01%
EPS Next 2Y17.07%
EPS Next 3Y15.64%
EPS Next 5Y14.4%
Revenue Next Year19.72%
Revenue Next 2Y15.31%
Revenue Next 3Y13.68%
Revenue Next 5Y12.12%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BSX is valuated quite expensively with a Price/Earnings ratio of 33.67.
BSX's Price/Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Earnings ratio of 26.51, BSX is valued a bit more expensive.
The Price/Forward Earnings ratio is 28.85, which means the current valuation is very expensive for BSX.
BSX's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.53. BSX is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.67 | ||
| Fwd PE | 28.85 |
4.2 Price Multiples
61.67% of the companies in the same industry are cheaper than BSX, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as BSX.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.21 | ||
| EV/EBITDA | 33.13 |
4.3 Compensation for Growth
BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BSX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 15.64% in the coming years.
PEG (NY)1.68
PEG (5Y)3.52
EPS Next 2Y17.07%
EPS Next 3Y15.64%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:BSX (11/3/2025, 7:00:00 PM)
86.2
-0.2 (-0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap127.73B
Revenue(TTM)19.35B
Net Income(TTM)2.50B
Analysts86.34
Price Target110.26 (27.91%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)3.79%
PT rev (3m)5.17%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)2.16%
EPS NY rev (1m)0.02%
EPS NY rev (3m)2.19%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)2.16%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)2.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.67 | ||
| Fwd PE | 28.85 | ||
| P/S | 7.95 | ||
| P/FCF | 42.21 | ||
| P/OCF | 34.33 | ||
| P/B | 6.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 33.13 |
EPS(TTM)2.56
EY2.97%
EPS(NY)2.99
Fwd EY3.47%
FCF(TTM)2.04
FCFY2.37%
OCF(TTM)2.51
OCFY2.91%
SpS10.84
BVpS13.14
TBVpS-1.71
PEG (NY)1.68
PEG (5Y)3.52
Graham Number27.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.52 |
F-Score5
WACC8.27%
ROIC/WACC0.93
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y20.01%
EPS Next 2Y17.07%
EPS Next 3Y15.64%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year19.72%
Revenue Next 2Y15.31%
Revenue Next 3Y13.68%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX.DE FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.
What is the valuation status of BOSTON SCIENTIFIC CORP (BSX.DE) stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.
How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?
BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 4 / 10.
What is the expected EPS growth for BOSTON SCIENTIFIC CORP (BSX.DE) stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 20.01% in the next year.